

**Patient Information**

Patient Name: Jane Doe  
 Date of Birth: 11/08/1975  
 Maternal Age at EDD: 37  
 Gestational Age: 11 weeks/0 days  
 Maternal Weight: N/A  
 Patient ID: P99457  
 Medical Record #: M84555  
 Collection Kit: 123233-2-N  
 Reference ID: 254233-2-N  
 Accessioning ID: C47695  
 Case File ID: 159466

**Test Information**

Ordering Physician: Dr. Matthew Goodbirth, M.D. (G123456)  
 Clinic Information: Natera, Inc.  
 Additional Reports: N/A  
 Report Date: 02/01/2013  
 Samples Collected: 01/31/2013  
 Samples Received: 02/01/2013  
 Mother Blood



**ABOUT THIS SCREEN:** Panorama™ is a screening test, not diagnostic. It evaluates genetic information in the maternal blood, which is a mixture of maternal and placental DNA, to determine the chance for specific chromosome abnormalities. The test does NOT tell with certainty if a fetus is affected, and only tests for the conditions ordered by the healthcare provider. A low risk result does not guarantee an unaffected fetus.

**TEST SELECTED:** Sex of Fetus, Triploidy, Extended Panel

**FINAL RESULTS SUMMARY**

Result

**LOW RISK**

Fetal Sex

**Male**

Fetal Fraction

**8.3%**

Notes by the clinical reviewer, if any, will be shown here.

**RESULTS DETAILS**

Condition tested <sup>1</sup>	Result	Risk Before Test <sup>2</sup>	Panorama Risk Score <sup>3</sup>
Trisomy 21	Low Risk	1/152	< 1/10,000
Trisomy 18	Low Risk	1/111	< 1/10,000
Trisomy 13	Low Risk	1/357	< 1/10,000
Monosomy X	Low Risk	1/256	< 1/10,000
Triploidy/Vanishing twin	Low Risk		
22q11.2 deletion syndrome	Low Risk	1/2,000 <sup>4</sup>	1/13,300
1p36 deletion syndrome	Low Risk	1/5,000 <sup>4</sup>	1/12,400
Angelman syndrome	Low Risk	1/12,000 <sup>4</sup>	1/16,600
Cri-du-chat syndrome	Low Risk	1/20,000 <sup>4</sup>	1/57,100
Prader-Willi syndrome	Low Risk	1/10,000 <sup>4</sup>	1/13,800

1. Excludes cases with evidence of fetal and/or placental mosaicism. 2. Based on maternal age, gestational age, and/or general population, as applicable. References available upon request. 3. Based on a priori risk and results of analysis of circulating placental DNA.

**Testing Methodology:** DNA isolated from the maternal blood, which contains placental DNA, is amplified at specific loci using a targeted PCR assay, and sequenced using a high-throughput sequencer. Sequencing data is analyzed using Natera's proprietary algorithm to determine the fetal copy number for chromosomes 13, 18, 21, X, and Y, thereby identifying whole chromosome abnormalities at these locations, and if ordered, the microdeletion panel will identify microdeletions at the specified loci only. If a sample fails to meet the quality threshold, no result will be reported for the specified chromosome(s). The test requires sufficient fetal fraction to produce a result.

**Disclaimers:** This test has been validated on women with a singleton pregnancy and of at least nine weeks gestation. A result will not be available where the maternal blood cells and oocytes are not of the same genetic lineage, as in the case of an egg donor, surrogate, or bone marrow transplant recipient. Findings of unknown significance will not be reported. As this assay is a screening test and not diagnostic, false positives and false negatives can occur. High risk test results need diagnostic confirmation by alternative testing methods. Low risk results do not fully exclude the diagnosis of any of the syndromes nor do they exclude the possibility of other chromosomal abnormalities or birth defects, which are not a part of this test. Potential sources of inaccurate results include, but are not limited to, mosaicism, low fetal fraction, limitations of current diagnostic techniques, or misidentification of samples. This test will not identify all deletions associated with each microdeletion syndrome. This test has been validated on full region deletions only and may be unable to detect smaller deletions. Microdeletion risk score is dependent upon fetal fraction, as deletions on the maternally inherited copy are difficult to identify at lower fetal fractions. Test results should always be interpreted by a clinician in the context of clinical and familial data with the availability of genetic counseling when appropriate. The Panorama prenatal test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

Approved By: Gregory M. Enns, MB, ChB, FAAP

Approved By: Susan Zneimer, Ph.D., FACMGG, Laboratory Director

IF THE ORDERING PROVIDER HAS QUESTIONS OR WISHES TO DISCUSS THE RESULTS, PLEASE CONTACT US AT 650-249-9090 #3. Ask for the NIPT genetic counselor on call.

CLIA ID#05D1082992; Rev DEV\_BUILD

Report IDLowRisk/MDFullPanelNoFather\_V3

Natera, Inc., 1-855-866-NIPT (6478)

201 Industrial Road Suite 410, San Carlos, CA 94070

